Argenx CIDP Data Set To Attract Big Pharma Suitors
Pipeline-In-A-Product Vyvgart Sweeps Through Another Phase III
The very positive Vyvgart ADHERE data in chronic inflammatory demyelinating polyneuropathy, the recent approval for the subcutaneous version for generalized myasthenia gravis and the drug's already strong sales mean that Argenx will again be at the top of the M&A targets tree.
